Cystic fibrosis is a life threatening, inherited disease of the exocrine glands. The condition primarily affects the digestive and respiratory systems which become clogged with a thick, sticky mucus. Cystic fibrosis is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in an excess of salt and water passing into cells, causing a thick, sticky mucus to build up in bodily passageways.
Proteins are the messengers, workers, managers, and directors of mostly all intra- and inter-cellular functions in the human body.
Mucus is an essential protective layer of gel-like liquid composed largely of proteins called mucins throughout our airways.
Mycobacterium abscessus, a relative of the bacteria that cause tuberculosis and leprosy, is responsible for particularly severe damage to human lungs and can be resistant to many standard antibiotics, making infections extremely challenging to treat.
A team of scientists rectified mutations that result in cystic fibrosis in cultured human stem cells.
A study released today in STEM CELLS Translational Medicine offers hope for those suffering from a chronic, difficult to treat condition called non-tuberculous mycobacteria (NTM) lung infection.
A new approach to gene editing using the CRISPR/Cas9 system bypasses disease-causing mutations in a gene, enabling treatment of genetic diseases linked to a single gene, such as cystic fibrosis, certain types of sickle cell anemia, and other rare diseases.
Scientists have created a CRISPR-based gene editor named C-to-G Base Editor (CGBE) that can correct mutations responsible for genetic disorders.
Scientists have developed an affordable, downloadable app that scans for potential unintended mistakes when CRISPR is used to repair mutations that cause disease.
Scientists who highlighted the bug-busting properties of bacteria in Northern Irish soil have made another exciting discovery in the quest to discover new antibiotics.
Researchers from Johns Hopkins University and Medicine have designed a potential new antibiotic for a pathogen that is highly resistant to drugs and is often lethal to individuals suffering from lung diseases, including cystic fibrosis.
For the first time, researchers have successfully created airway basal stem cells in vitro from induced pluripotent stem cells by reprogramming blood cells taken from patients.
The vast majority of bacteria in the world live on surfaces by forming structures called "biofilms". These communities host thousands to millions of bacteria of different types, and are so biologically complex and active that scientists describe them as "cities".
A new and quicker method of diagnosing diseases in patients has been created by researchers at the University of Leeds.
A new study shows that in addition to blood, endurance exercise induces changes in sweat biomolecule levels. These findings lay the groundwork for the development of future noninvasive exercise monitoring systems that utilize sweat as a biomarker source.
A group of biomolecular engineers from Rice University has now identified a C-worthy method that significantly improves the precision of gene editing.
World-first research led by Monash University could hold the key to better monitoring and treatment of lung disease associated with cystic fibrosis (CF) - a condition thousands of people are diagnosed with each year.
The genome in mitochondria -- the cell's energy-producing organelles -- is involved in disease and key biological functions, and the ability to precisely alter this DNA would allow scientists to learn more about the effects of these genes and mutations.
Professor Dr. Robert P. Doyle has developed a new drug to treat type 2 diabetes in millions of patients who are seeking to better control their blood sugar.
After examining the genes of more than 200,000 people all over the world who have type-2 diabetes, researchers from the Perelman School of Medicine at the University of Pennsylvania and the Veterans Health Administration's Corporal Michael J. Crescenz Veterans Affairs Medical Center found hundreds of genetic variants never before linked to the disease.
Through serendipity, researchers at the University of Pittsburgh Graduate School of Public Health considerably reduced the toxicity of a potential antibiotic against the most feared drug-resistant bacteria, while also improving its stability in fighting infections.